![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, October 25, 2018 1:28:22 PM
Investors take note, in the documents of the tests performed by ABiCh lab in Quebec presented in section 2.1 of the Study Design as "Aim of the Test" CLEARLY STATES (quote)
"The challenge test is a predictive method useful to evaluate the effectiveness of a preservation system used in the formulation of a COSMETIC PRODUCT."
AND in section 2.3 under "product description" CLEARLY STATES (quote)
"representing the protection capacity of a COSMETIC FORMULATION."
So the evidence & proof the company is supplying in print CLEARLY STATES THIS IS A COSMETIC PRODUCT.
Why are they (RBII) touting this in audio/press releases as medicine that "doctors can write a prescription for" when this is nothing more than another retail item for which there are VERY different FDA guidelines as opposed to prescription items???
Thank you Wall Street Kid & Hunchbackgeek for supplying proof the company is SAYING something very different about their products than what they are actually producing or testing. Good solid info.
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM